You are here

CAR T Cells: Engineering a patient's immune cells to treat their cancer

sandy craine's picture
Submitted by sandy craine on Thu, 02/11/2017 - 4:20pm

Over the last two decades, targeted therapies like imatinib (Gleevec®)and trastuzumab (Herceptin®)—drugs that target cancer cells by homing in on specific molecular changes seen primarily in those cells—have also cemented themselves as standard treatments for many cancers.

Targeted Antibiotic Use May Help Cure Chronic Myeloid Leukaemia

sandy craine's picture
Submitted by sandy craine on Thu, 21/09/2017 - 1:13pm

The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research. ‌

The University of Glasgow led study, published today in Nature Medicine, demonstrates the effectiveness of combining tigecycline with the drug imatinib – a tyrosine kinase inhibitor (TKI) and standard first-line treatment of patients with CML.

 

Stopping Drug Therapy for CML: EURO-SKI Results

sandy craine's picture
Submitted by sandy craine on Sat, 29/07/2017 - 5:26pm

European Stop TKI Study (EURO-SKI), show that stopping TKI therapy is feasible and that about half of patients remain free from relapse after 2 years of follow-up.
A further analysis of patients who were taking imatinib suggests that stopping imatinib after 5.8 years is associated with a higher likelihood of molecular relapse-free survival.
The results were presented here at the American Society of Hematology (ASH) 2016 Annual Meeting (abstract 787).

Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients

sandy craine's picture
Submitted by sandy craine on Sat, 29/07/2017 - 12:26pm

 

Introduction:

The hallmark of chronic myeloid leukemia (CML) is the presence of Philadelphia chromosome, its resultant fusion transcript (BCR-ABL1), and fusion protein (p210). Alternate breakpoints in BCR (m-bcr, μ-bcr, and others) or ABL1 result in the expression of few rare fusion transcripts (e19a2, e1a2, e13a3, e14a3) and fusion proteins (p190, p200, p225) whose exact clinical significance remains to be determined.

Striving to vanquish leukaemia: Combination of two compounds shows promise in the lab

sandy craine's picture
Submitted by sandy craine on Thu, 20/07/2017 - 5:39pm

Cancer cells are escape artists by nature. They can dodge drugs designed to cripple them due to one of their defining characteristics: their genetic makeup changes rapidly. Cancer cells are constantly evolving, and, given the right mutation, they’re able to evade treatment.

Treatment-free remission following frontline nilotinib in patients with CML in chronic phase: results from the ENESTfreedom study

sandy craine's picture
Submitted by sandy craine on Sat, 08/07/2017 - 5:15pm

A Hochhaus1, T Masszi2, F J Giles3, J P Radich4, D M Ross5, M T Gómez Casares6, A Hellmann7, J Stentoft8, E Conneally9, V García-Gutiérrez10, N Gattermann11, W Wiktor-Jedrzejczak12, P D le Coutre13, B Martino14, S Saussele15, H D Menssen16, W Deng17, N Krunic18, V Bedoucha16 and G Saglio19

Natural Killer Cell Counts Are Associated With Molecular Relapse-Free Survival After Imatinib Discontinuation

sandy craine's picture
Submitted by sandy craine on Sat, 10/06/2017 - 5:16pm

Imatinib Discontinuation In Chronic Myeloid Leukemia: The IMMUNOSTIM Study

Despite leukemic stem cell persistence, patients with chronic myeloid leukaemia who achieve and maintain deep molecular responses may successfully stop the tyrosine kinase inhibitor imatinib. However, questions remain unanswered regarding the biological basis of molecular relapse after imatinib cessation. In IMMUNOSTIM, we monitored 51 patients from the French Stop IMatinib trial for peripheral blood T-cells and natural killer cells. 

Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy

sandy craine's picture
Submitted by sandy craine on Sat, 13/05/2017 - 3:54pm

Burwick, Richard M. MD, MPH; Kuo, Kelly MD; Brewer, Diana PA; Druker, Brian J. MD

BACKGROUND: Pregnant women with chronic myeloid leukemia (CML) can be treated effectively with the tyrosine-kinase inhibitor imatinib, but data regarding fetal and neonatal exposure and safety are limited.

 

CASE: We present a patient with newly diagnosed CML in early pregnancy. Leukapheresis and interferon-α were initiated in the second trimester with limited benefit. 

Strategies for Stopping TKIs Growing Clearer

sandy craine's picture
Submitted by sandy craine on Sun, 02/04/2017 - 3:34pm

In patients with chronic myeloid leukemia (CML), longer treatment duration is associated with an increase in the odds ratio for preserving a major molecular response (MMR) six months after discontinuing tyrosine kinase inhibitor (TKI) therapy, according to recent data from a large study. In contrast, the depth of molecular response was not a predictor of molecular relapse-free survival (MRFS).

Pages